8 completed, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 1, 3 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
Follow voxilaprevir: new trials by email Literature Review of voxilaprevir trials Research Report on voxilaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| The Efficacy of Vosevi in Treating DAA-experienced Patients Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C, Medication Reaction | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | 200 | 2023-02-28 | 2024-03-13 | |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol - HCV Infection | Phase 1 | Completed | Gilead Sciences | 15 | 2015-10-29 | 2020-09-02 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment Voxilaprevir - HCV Infection | Phase 1 | Completed | Gilead Sciences | 20 | 2015-05-05 | 2020-03-20 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment Voxilaprevir - HCV Infection | Phase 1 | Completed | Gilead Sciences | 33 | 2015-03-24 | 2020-04-09 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection VOX, SOF/VEL, RBV - Hepatitis C Virus Infection | Phase 2 | Completed | Gilead Sciences | 205 | 2015-02-17 | 2020-03-06 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection VOX, SOF/VEL - Hepatitis C Virus Infection | Phase 2 | Completed | Gilead Sciences | 128 | 2015-02-16 | 2020-03-03 |
| Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection LDV/SOF, RBV, SOF/VEL - Chronic Hepatitis C | Phase 2 | Completed | Gilead Sciences | 273 | 2014-08-04 | 2018-11-16 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL - Hepatitis C Virus Infection | Phase 1 | Completed | Gilead Sciences | 101 | 2014-06-13 | 2020-09-17 |
Hepatitis C (6) · Hepatitis C, Chronic (4) · Digestive System Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · Hepatitis, Viral, Human (1) · Liver Diseases (1) · Liver Neoplasms (1) · Picornaviridae Infections (1) · RNA Virus Infections (1) · Recurrence (1)
Gilead Sciences (7) · Helwan University (1) · M.D. Anderson Cancer Center (1) · Qing XIe (1) · The Third Affiliated Hospital of Guangzhou Medical University (1)
New Zealand (6) · United States (6) · Puerto Rico (3) · China (2) · Germany (2) · Egypt (1)
Harrys A. Torres, MD (1) · Qing Xie, MD (1) · Xingfei Pan, PhD (1)
PMID 27240903, PMID 27486033, PMID 27486034, PMID 28137593, PMID 29063860, PMID 37088312
2015 (2)